Filter your search
PharmaceuticalsX
Kalorama Information is a dependable resource for information on opportunity in the pharmaceutical market. The pharma industry has seen important developments in the last few years, bringing both challenges and new opportunities. The industry outlook for many manufacturers has changed due to outsourcing in drug discovery, growing generic competition and greater interest in biotechnology, among other developments. Our reports provide the sales data, revenue forecasts, and competitive analysis that one needs to understand the market.
Vaccines
Drug Delivery
Over-the-Counter
Drug Discovery
Cancer Treatment
Manufacturing & Packaging
Prescription Drugs
- $2,500.00 – $7,000.00The landscape of generic companies is changing: their relative might in the industry is increasing and the product lines their offering are growing in depth and breadth. Strong growth in the sector has come not only from more aggressive tactics and better acceptance in the clinical and consumer population, but by the loss of patent […]April 1, 2006$3,500.00 – $7,000.00There are hundreds of drugs in Phase III clinical trials, of which almost 200 of them may gain market approval from the FDA in the coming 5 years. Which drugs will make it and how these drugs impact existing pharmaceutical markets in terms of overall size and competitive share is one of the most difficult […]March 1, 2006$3,500.00 – $7,000.00The strategic interplay of of HIV/AIDS diagnostics and therapeutics is one of the most complex that the healthcare industry has ever seen. In order to cope with the challenges and opportunities of HIV/AIDS, companies must think on a global basis, and in addition to the basic pathology and complications of HIV/AIDS, there are societal and […]March 1, 2006$2,200.00 – $5,990.00Biopharmaceutical research and development is sure to dramatically increase the number of injectable drugs coming to market over the next few years. While advanced drug delivery techniques continue to hold promise for unique methods of administration, the traditional injection is still the dominant paradigm. However, the staggering costs and intransigent safety problems associated with sharps, […]February 18, 2006$1,995.00 – $7,800.00This report provides the reader with a comprehensive analysis of the domestic and international markets involving pharmaceuticals to treat skin diseases and disorders. This edition of Worldwide Market for Prescription Dermatologic Drugs is the fifth time Kalorama Information has comprehensively studied the dermatology markets. As is the case with each new edition, Kalorama completely re-evaluated […]February 1, 2006$3,000.00 – $6,000.00The private label over-the-counter (OTC) market has been gaining ground rapidly over the past five years. The private label sector has shed its image of being a ‘me-too’ version of national brands and worked toward offering quality and innovation at an economical price. With benefits for consumers, retailers, and manufacturers, private label healthcare should experience […]February 1, 2006$995.00 – $5,990.00With the mapping of the human genome and the concomitant explosion of proteomics, a steady stream of biopharmaceuticals have been launched—recombinant therapeutic proteins, monoclonal antibody-based products used for therapeutic or in vivo diagnostic purposes, and nucleic acid-based products. As the rate of regulatory approval for biopharmaceuticals increases, the number of products reaching the market will […]January 1, 2006$2,995.00 – $5,990.00In the Spring of 2003, Kalorama published its first report on Outsourcing in Drug Discovery. Since then, so much has changed, the use of the term “2nd Edition” hardly seems appropriate. This new study involved completely re-examining the market from the ground up. This new report is designed to make readers aware of the enormous […]January 1, 2006$3,000.00 – $6,000.00The U.S. Market for OTC anti-infective products surpassed the $2 billion mark last year. Although overall growth is sluggish, the market is a proven revenue source for a number of major brands, and there have been some nice surprises in the performance of some categories, such as first-aid related antiseptic and antibiotic products. This comprehensive […]January 1, 2006$2,500.00 – $5,000.00Some of the biggest-selling biological drugs developed during the first phase of the biotechnology revolution in the 1980s, including human growth hormone (hGH) and insulin, are set to lose patent protection in the United States in 2005 and soon after. This opens up a market currently worth over $30 billion (and growing at over 10% […]November 1, 2005
